company_id,name,ticker,legal_name,incorporation_date,sector,sub_sector,industry_classification,hq_city,hq_state,hq_country,regions_operated,founder_names,founding_story_summary,mission_statement,ownership_status,listed_exchange,isin,cik_like,lei_like,fiscal_year_end,employees_2020,employees_2021,employees_2022,employees_2023,employees_2024,employees_2025_ytd,union_presence_pct_2024,remote_work_pct_2024,primary_products,primary_services,core_ip_assets,patent_count_2025,subsidiaries,banking_partners,major_customers,major_suppliers,go_to_market_strategy,pricing_model,primary_cloud_provider,erp_system,crm_system,data_stack,security_certifications,environmental_goals,diversity_goals,esg_policy_summary,risk_register_top3,competitors,regulators,accounting_standard,tax_jurisdictions,transfer_pricing_method,credit_rating_internal,cash_management_policy,treasury_risk_limits,board_size,board_committees,board_independence_pct_2024,auditor,legal_counsel,pr_agency,investor_relations_contact,media_contact,careers_url_placeholder,website_placeholder,status
C016,NanoMed Therapeutics,NANO,"NanoMed Therapeutics Inc.",2019-02-14,"Biotechnology","Nanomedicine & Drug Delivery","NAICS 325412; SIC 2834; GICS 35201020","San Francisco",California,USA,"North America; Europe; Asia","Dr. Elena Vasquez; Dr. Raj Kumar","Founded by nanotechnology researchers to develop targeted drug delivery systems using engineered nanoparticles for cancer treatment and precision medicine applications.","To revolutionize medicine through precision nanotherapeutics that deliver drugs exactly where needed while minimizing side effects and maximizing therapeutic impact.","Private",N/A,N/A,0004567890,549300NANO345678,"December 31",180,320,450,580,740,810,6,72,"NanoTarget Cancer Therapy; PrecisionDx Diagnostic Nanoparticles; NanoCarrier Drug Delivery Platform","Drug formulation development; clinical trial support; regulatory consulting","Targeted nanoparticle engineering; biocompatible polymer chemistry; controlled drug release mechanisms",42,"NanoMed Europe GmbH (Basel); NanoMed Asia Ltd (Singapore)","Merrill Lynch; Swiss Bank Corporation","Pfizer; Roche; Johnson & Johnson; Medisafe Health","BASF (polymer materials); Evonik (specialty chemicals); Borealis CloudWorks (C003) for clinical data analytics","Pharma partnership model; licensing agreements; direct clinical development collaborations","Licensing fees + milestone payments + royalty sharing on commercialized products","Borealis CloudWorks (C003) for clinical analytics with AWS for backup","Oracle ERP Cloud","Salesforce Life Sciences Cloud","Snowflake; Apache Spark; R/Bioconductor; custom pharmacokinetic modeling","ISO 13485; GMP compliance; FDA IND approved; EMA scientific advice","Carbon-neutral R&D operations by 2030; 90% green chemistry processes; sustainable nanoparticle production","50% women in senior scientific positions by 2028; STEM diversity programs; equitable clinical trials","ESG framework emphasizes patient safety, environmental responsibility in nanomaterial production, and inclusive clinical research.","1. Clinical trial failure risk; 2. Regulatory approval uncertainty; 3. Manufacturing scale-up complexity","Moderna (LNP technology); BioNTech; Selecta Biosciences; Nanobiotix","FDA; EMA; PMDA; Health Canada","US GAAP","USA; Switzerland; Singapore","TNMM with pharmaceutical sector benchmarks","BBB (positive outlook), internal","Maintain 12 months liquidity; 40% cash in pharmaceutical sector bonds; clinical milestone tracking","Daily VaR $1.2M; max pharma partner exposure $10M; currency hedging for international trials",7,"Audit; Scientific Advisory; Compensation; Nominating & ESG",59,"KPMG","Cooley LLP","BioPharma Communications","ir@nanomed-therapeutics.com","press@nanomed-therapeutics.com","https://careers.nanomed-therapeutics.com","https://www.nanomed-therapeutics.com",Active
